Company: HCTI
Filing Date: 2025-05-15
Form Type: 424B4
Source: 0001213900-25-044095
Chunk: 21

Company: Healthcare Triangle, Inc.
Filing Date: 2025-05-15
Form: 424B4
Chunk 21
---
 the Panel approved the Company’s
request for the Panel to consider it in compliance with the Stockholders’ Equity Rule, if by February 28, 2025, it disclosed in
a public filing that it believed it had regained compliance with the Stockholders’ Equity Rule and the event that occurred resulting
in such compliance. On February 28, 2025, the Company publicly disclosed in a Current Report on Form 8-K that it believed it was in compliance
with the Rule as a result of receiving net proceeds of approximately $13.68 million from the Private Placement (as defined below).

The purpose of the Private Placement was for
the Company to regain compliance with the Stockholders’ Equity Rule and to increase its working capital.

Terms of Private Placement

On February 27, 2025,
we entered into Securities Purchase Agreements with the selling stockholders for the private placement (the “Private Placement”)
of 36,190,485 Units, each Unit consisting of (i) one share of Common Stock; (ii) a Pre-Funded Warrant to purchase one share of common
stock; a Series A Warrant to purchase one share of common stock and one Series B Warrant to purchase one share of common stock at an
offering price of $0.42 per Unit (or $0.41999 per Unit in the case of Units that include pre-funded warrants). The Common Stock, the
Pre-Funded Warrants and the Purchase Warrants included in the Units and the Common Stock underlying the Pre-Funded Warrants and the Purchase
Warrants are collectively referred to herein as the “Securities” and the Securities, other than the Pre-Funded Warrants,
and the Purchase Warrants shall be referred to herein as the “Registrable Securities.” The entire transaction was priced
at the market under Nasdaq rules and closed on February 28, 2025.

The initial exercise price
for both the Series A Warrants and Series B Warrants is $0.84 per share and both the Series A Warrants and Series B Warrants terminate
on the fifth anniversary of the earlier of (i) the effective date of the registration statement related to this prospectus (the “Registration
Statement”) or (ii) the date that the Registerable Securities can be sold, assigned or transferred without restriction or limitation
pursuant to Rule 144 promulgated under the 1933 Act, as amended. The Purchase Warrants became exercisable on March 23, 202